4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner

Journal of Immunology

Volumn 169, Issue 4, 2002, Pages 1792-1800

  Miller, Robert E ^a   Jones, Jon ^a   Le, Tiep ^a   Whitmore, James ^a   Boiani, Norman ^a   Gliniak, Brian ^a   Lynch, David H ^a  

^a Department of Cancer Biology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4 1BB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

EID: 0037103147     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.4.1792     Document Type: Article

References (50)

1. Role of TGF-β in immune-evasion of cancer
2. A fresh look at tumor immunosurveillance and immunotherapy
3. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: Lessons from recurrent tumors
4. Ultraviolet light induced murine suppressor lymphocytes dictate specificity of anti-ultraviolet tumor immune responses
5. Modulation of immunoregulatory responses directed toward various tumor antigens within hosts possessing distinct immunologic potentials
6. Evidence for two functionally distinct cross-reactive tumor antigens associated with ultraviolet light and chemically induced tumors
7. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colonystimulating factor and interleukin-6 cells
8. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells
9. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
10. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
11. Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice
12. CD28/B7 system of T cell costimulation
13. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity
14. Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma
15. Dendritic cells and the control of immunity
16. Dendritic cells (I): Biological functions
17. Dendritic cells as adjuvants for immune-mediated resistance to tumors
18. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones
19. Induction of T cell anergy in the absence of CTLA-4/B7 interaction
20. + T cells become nonresponsive (anergic) following activation in the presence of costimulation
21. + T cells in vitro
22. Review article: Molecular signals and genetic reprogramming in peripheral T-cell differentiation
23. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy
24. Costimulatory wars: The tumor menace
25. CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation
26. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
27. The role of B7-CD28 co-stimulation in tumor rejection
28. Flt3 ligand induces tumor regression and antitumor immune responses in vivo
29. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo
30. + T cells
31. Generating a T cell tumor-specific immune response in vivo: Can flt3-ligand-generated dendritic cells tip the balance?
32. Antitumor effects of α-interferon and γ-interferon on a murine renal cancer (Renca) in vitro and in vivo
33. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma
34. Molecular and biological characterization of human 4-1BB and its ligand
35. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
36. Costimulation of antigen-specific CD4 T cells by 4-1BB ligand
37. + T lymphocytes by 4-1BB ligand
38. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
39. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies
40. + murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells
41. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice
42. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway
43. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation
44. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus
45. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses
46. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal
47. + memory T cells by opposing cytokines
48. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo
49. + T cells
50. A role of interferon-γ (IFN-γ) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-γ-deficient mice